ArticlePLOS global public health2026
Policies and strategies for HPV vaccination schedule completion in immunocompromised girls, including girls living with HIV: Qualitative insights from Eswatini, Malawi, and Uganda.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunocompromised girls, including girls living with HIV, face significantly increased risk for HPV-linked cervical cancer and require a differentiated human papillomavirus (HPV) vaccination schedule. While World Health Organization (WHO) vaccination guidelines exist, recommending immunocompromised individuals receive at least two, if possible three doses of HPV vaccine, little is known about how country health programs implement these recommendations. This study examines HPV vaccination policies, delivery strategies, barriers, and enablers for immunocompromised girls in Eswatini, Malawi, and Uganda-countries with a high burden of HIV and cervical cancer. A cross-sectional qualitative study was conducted through key informant interviews and focus group discussions with stakeholders from ministries of health, implementing partners, and health workers. A desk review of relevant policy documents was also conducted. Data were analyzed thematically to identify common and country-specific themes. All three countries follow the WHO's recommendation for a two-dose HPV vaccine schedule for immunocompromised girls. However, none have fully documented or consistently implemented policies or delivery strategies to reach immunocompromised girls with additional HPV vaccination doses. Stakeholder awareness of dosing schedules and strategies to vaccinate immunocompromised girls was limited and inconsistent, though higher in Eswatini than in Malawi or Uganda. Promising strategies were identified across the three countries, including use of Teen Clubs and adolescent HIV clinics to deliver HPV vaccines. Barriers included stigma, limited cold chain infrastructure, unclear operational policies, and weak data systems. Enablers included trusted health provider relationships, peer mentorship, and community awareness of cervical cancer risks. Improving HPV vaccine delivery for immunocompromised girls, including girls living with HIV, will require documenting and disseminating clear policies, integrating vaccination into HIV and adolescent health services, scaling successful strategies, and strengthening data systems to monitor coverage. Tailored, stigma-sensitive strategies are essential to ensure equitable cervical cancer prevention for immunocompromised adolescents in high HIV-burden settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.